Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers by Jernvall, P et al.
Colorectal cancer is the second most common cancer in many
Western countries. Outcome among such patients is often poor,
with a mean 5-year relative survival rate of around 50% (Mäkelä et
al, 1995; Sant et al, 1995). Prognosis is dependent on the stage of
the disease at the moment of diagnosis. In patients with the least
advanced Dukes’ classes A and B tumours, 5-year cumulative
survival is as good, 95% and 70% respectively, whereas it is
around 30% in patients with the more advanced Dukes’ class C,
and in patients with the primarily metastatic Dukes’ class D it is
only 2% (Arveux et al, 1997).
Surgery is the most efficient therapy in colorectal cancer.
Despite radical surgical treatment, tumour recurrence occurs in
30–40% of cases (Mäkelä et al, 1995; Obrand and Gordon, 1997).
The use of adjuvant therapies in preventing recurrence, especially
in patients with Dukes’ class C colon and rectal cancers, and also
in some patients with Dukes’ class B rectal cancer, is continuously
increasing. These therapies have side-effects, and thus they should
be given only to those who really benefit from them, which actu-
ally means they should be given to those patients prone to develop
a recurrent tumour (Fielding et al, 1992; Swedish Rectal Cancer
Trial, 1996). These recurrences cannot be reliably predicted by any
means at the moment of primary operation. Thus, targeting of
adjuvant therapies is nowadays based only on the primary stage of
the disease, not on the presence of any specific ‘marker’ related to
the development of recurrent tumours (Vernava et al, 1994).
Allelic loss (loss of heterozygosity, LOH) in the long arm of
chromosome 18 can be detected in about 60–70% of colorectal
cancer cases. The most frequent area of loss is 18q21–qter, where
the candidate tumour-suppressor genes MADR2, DPC4 and DCC
are known to reside (Fearon et al, 1990; Thiagalingam et al, 1996).
The area has not been fully examined, and it is believed that other
tumour-suppressor genes are likely to be found there in the near
future (Eppert et al, 1996). In previous studies, mostly carried out
with relatively small or selected patient groups, LOH in this area
has been suggested to be predictive of metastasis and poor prog-
nosis (O’Connell et al, 1992; Iino et al, 1994; Jen et al, 1994;
Frank et al, 1997).
In order to clarify the value of LOH at 18q21 as a marker in
colorectal cancer prognosis, we have undertaken a comprehensive
analysis of 255 (of which 195 were informative) colorectal cancers
as regards LOH at 18q21 and correlated our findings with patient
outcome. Allele status was correlated with clinical and pathological
features of the tumour, such as its location, stage of disease, histo-
logical grade, mucinous cancer type and development of recurrence.
Survival analysis was carried out in correlation with LOH status.
MATERIALS AND METHODS
Patients
The status of chromosome 18 long arm area 21 was studied in 255
patients operated upon in 1986–91 and 1993–96 for primary
colorectal cancer in order to evaluate the possible clinical impor-
tance of loss of heterozygosity in this region. Of these 255
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Oulu, Kajaanintie 50, FIN-90220 Oulu, Finlandpatients, 195 were informative as regards LOH status. Excluded
from the study were 28 replication error-positive cases and 32
cases that were uninformative as a result of homozygous genotype
or sampling problems. In data handling, only cases informative as
regards LOH were taken into account.
Of the 195 patients, 105 (54%) were men and 90 (46%) were
women. The age distributions were from 24 to 88 years in men
(mean 66) and from 38 to 93 years in women (mean 68). Follow-
up was organized as described by Mäkelä et al (1995). The follow-
up time ranged from 2 to 138 months (mean 40) and ended on the
30 August 1997 or at the moment of death. Case records and
cancer registry files (Finnish Cancer Registry) were used to eval-
uate the medical history of the patients and clinical aspects of the
disease. The original microscopy slides were reviewed separately
by two pathologists to confirm the pathological grading and
staging. Grading was carried out according to the World Health
Organization histological classification system (Jass and Sobin,
1989). Patients were in histological grades as follows: I, 46 (26%);
II, 107 (61%); III, 23 (13%). Of the tumours, 19 were of mucinous
type. Staging was carried out on the basis of histological and
clinical examinations according to the Turnbull modification
of Dukes’ classification: A, 48 (24.6%); B, 78 (40.0%); C, 45
(23.1%); and D, 24 (12.3%) (Turnbull et al, 1967). Tumours
occurring from the caecum to the splenic flexure were considered
proximal (49, 25%), and those from the descending colon to the
rectum distal (146, 75%) (Ponz de Leon et al, 1992).
In the analyses related to recurrence, only patients curatively
operated upon prior to 30 August 1995 were included, in order to
achieve sufficient follow-up time. A minimum follow-up time of 2
years was established because the majority, about 85%, of
colorectal cancer recurrence is known to occur within 2 years of
the primary operation (Mäkelä et al, 1995). Recurrence is consid-
ered local if in the area of anastomosis or having invaded out of the
primary resection area but having no distant metastases, and
distant if there is distant metastasis (Mäkelä et al, 1995).
DNA extraction
Blood samples and fresh tissue specimens were collected at the
primary operation from those patients operated upon in 1993–96.
Paraffin-embedded archival material was available from those
patients primarily operated upon in 1986–91.
The specimens were evaluated by two experienced pathologists
as described previously (Jernvall et al, 1997). Areas with the highest
proportion of neoplastic cells were dissected and used as tumour
samples. Normal tissue or blood was used as a control. DNA extrac-
tion from fresh tissue and blood samples was performed as previ-
ously described (Elo et al, 1995), as was DNA extraction from
paraffin-embedded tissue (Wright and Manos, 1990).
Microsatellite markers and polymerase chain reaction
(PCR)
Microsatellite markers were used to study the status of chromo-
some 18 long arm region 21. Cases with a minimum of two infor-
mative microsatellite markers in this region, were included in the
study. A tumour expressing LOH in a minimum of two markers
was considered LOH positive. Those samples expressing new
alleles were considered replication error positive (RER positive)
and were excluded from the study (Jen et al, 1994). The markers,
chosen from the Gènèthon human genetic linkage map
(ftp://ftp.resgen.com/pub), were, from telomere to centromere,
D18S58, D18S61, D18S55, D18S69, DCC, D18S474 and D18S65
(Dib et al, 1996). In each primer pair one primer was fluorescently
labelled for allele detection using a 381 A DNA Synthesizer
(Applied Biosystems, Foster City, CA, USA). The PCR reactions
contained 100 ng of DNA as template, 0.6 mg of each primer, four
deoxynucleotidetriphosphates (200 mM of each; Pharmacia LKB
Biotechnology, Uppsala, Sweden), 2 ml of 10 ´ reaction buffer IV
(200 mM ammonium sulphate, 750 mM Tris-HCl, pH 9.0 at 25°C,
0.1% w/v Tween), 1.75 mM magnesium chloride and 0.5 U of Red
Hot DNA polymerase (Advanced Biotechnologies, Surrey, UK) in
a 20 ml reaction volume. The PCRs were run in the following
conditions: denaturation at 95°C for 3 min followed by 35 cycles
(fresh tissue and blood) or 45 cycles (paraffin-embedded samples)
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Table 1 LOH in relation to clinicopathological features of the tumours
LOH– LOH+ P-value
n % n %
Dukes’ class
A 31 65 17 35 0.028
B3 4 4 4 4 4 5 6
C1 6 3 6 2 9 6 4
D1 3 5 4 1 1 4 6
Grade
I 25 54 21 46 0.19
II 44 41 63 59
III 13 57 10 43
Mucinotic 12 63 7 37 0.16
Non-mucinotic 82 47 94 53
Tumour location
Caecum 13 65 7 35 0.13
Ascending colon 7 70 3 30
Hepatic flexure 2 33 4 66
Transverse colon 3 43 4 57
Splenic flexure 3 50 3 50
Descending colon 5 71 2 29
Sigmoid colon 15 34 29 66
Recto-sigmoid 6 75 2 25
Rectum 40 46 47 54
Cancer
123.39
127.57
7033
23561
Normal
155.18
163.43
161.21
163.21 Normal 123.29
127.50
10058
10768
Cancer
Figure 1 (A) A cancer representative of allelic loss (upper) and a
corresponding normal tissue sample (lower). (B) A cancer representative of
RER-positivity (upper) and a corresponding normal tissue sample (lower)
A Bconsisting of denaturation at 95°C for 1 min, annealing at 53°C for
0.45–1.5 min and extension at 72°C for 1 min. Final extension
after the cycles was at 72°C for 10 min.
Gel analysis
The amplification product of each marker was mixed with 0.25 ml
of GS500-TAMRA size standard and 3.25 ml of loading buffer
(Applied Biosystems). From the mixture, 1.5 ml was then loaded
onto a Long Ranger 5% gel (FMC BioProducts, Rockland, ME,
USA) and the fragments were separated using an ABI Prism 377
automated fluorescent sequencer and further analysed with
GeneScan and Genotyper softwares (Applied Biosystems). The
two alleles of each sample were assigned according to the two
peaks of greatest height. Peak areas were compared with those
from the corresponding normal samples and an allele ratio was
calculated as described previously (Cawkwell et al, 1993). Those
samples with allele ratios <0.6 or >1.66 were considered LOH
positive. An example representative of allelic loss is shown in
Figure 1a, and an example representative of RER positivity is
shown in Figure 1b.
Statistical analysis
Pearson’s c2 test or exact tests (when appropriate) were used to
analyse statistical correlations between LOH and other variables.
Cumulative survival was assessed by the Kaplan–Meier method
and analysed by log-rank analysis. Perioperative deaths and other
deaths unrelated to colorectal carcinoma were censored at the time
of occurrence of the survival analysis. Multivariate analysis was
carried out by Cox regression analysis to determine independent
factors affecting survival. In all analyses, P < 0.05 was considered
statistically significant. The statistical procedures were performed
using SPSS software (SPSS, Chicago, IL, USA).
RESULTS
Of the 255 patients, 195 were informative as regards LOH status.
Loss of heterozygosity at 18q21 was found in 101 cases (52%). It
was equally common in women 47/90 (52%) and in men 54/105
(51%). The majority of instances of loss were found in tumours of
the distal colon or rectum: 80 of 101 LOH-positive tumours
(79%). LOH was most frequently found in tumours of Dukes’
classes B and C. In the primarily metastatic Dukes’ D class, LOH
was seen in less than half of the cases, and in the least advanced
Dukes’ class A in only one third of the cases. LOH was signifi-
cantly associated (P = 0.028) with the primary stage of the disease,
but it was not associated with the primary metastasis site in Dukes’
D tumours. Nor was it associated with the histological grade or
size of the tumour. Nineteen mucinous tumours were identified,
seven of them being LOH positive. Although LOH was less
frequently found in mucinous tumours, LOH negativity was not
significantly associated with the mucinous phenotype of cancer.
Clinicopathological features such as Dukes’ class, histological
grade, mucinocity and tumour location in relation to LOH status
are shown in Table 1. Analyses related to tumour recurrence were
performed on data from a group of 125 patients that had been cura-
tively operated upon at least 2 years prior to the end point of this
study in order to achieve sufficient follow-up time. Tumour recur-
rence was detected in 32% (40) of the cases; of these 57% (23)
were local and 43% (17) were distant recurrences. Of the recur-
rences, 85% occurred during the first 2 years of follow-up. The
appearance of a recurrent tumour was significantly associated with
LOH at 18q21 (P = 0.01). Of the primary tumours that recurred,
68% were LOH positive. The absence of LOH indicated recur-
rence-free disease in 78% of the cases (P = 0.01). Most recur-
rences appeared in patients with primary tumours of Dukes’
classes B and C (82%) (P = 0.005). Of the class B tumours, 25%
recurred and, of the class C tumours, 56% recurred. Of the recur-
rences, 87% (35) appeared in patients with primary disease of the
distal colon or rectum. The rate of recurrence in the LOH-positive
and LOH-negative groups in relation to Dukes’ class and location
of the tumour is shown in Table 2. The time from primary opera-
tion to diagnosis of recurrence did not differ between the LOH-
positive and the LOH-negative group; nor was the site of
recurrence associated with LOH status. Cumulative survival since
detection of recurrent disease was 62% at 1 year, 29% at 2 years
and 11% at 3 years, being similar in both groups.
Multivariate analysis was performed in order to identify inde-
pendent factors affecting survival. Dukes’ class, grade, tumour
location, age, gender and LOH status were included in the analysis
as covariates. Three separate analyses were carried out. In phase I,
18q21 LOH and recurrence in colorectal cancer 905
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Table 2 Recurrence in the LOH-positive and LOH-negative groups in
relation to Dukes’ class and tumour location
Recurrence
Overall rate LOH+ LOH–
n % n % n %
Dukes’ class
A 6/32 19 2 33 4 67
B 15/59 25 12 80 3 20
C 18/32 56 12 67 6 33
D 1/2 50 1 100 0 0
Location
Proximal 5/26 19 3 60 2 40
Distal 35/99 35 24 69 11 31
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Figure 2 Cumulative 5-year survival rates of LOH-positive (n = 101) and
LOH-negative (n = 94) patientsall 195 patients were included in the analysis, in phase II only
those patients included in the recurrence analysis were involved
and in phase III the analysis was carried out separately in each
Dukes’ class. The results of the analyses are shown in Table 3.
The overall cumulative 5-year survival rate for LOH-negative
and LOH-positive patients was 67% and 46% respectively (Figure
2). When Dukes’ D cases were excluded from the analysis, the 5-
year cumulative survival rates for LOH-negative and LOH-posi-
tive cases was 75% and 50% respectively. When the grade III and
Dukes’ D tumours were both excluded from the survival analysis,
as these appear to be strong, independent factors affecting
survival, the role of LOH at 18q21 became even more obvious,
with a 5-year cumulative survival rate of 78% in the LOH-nega-
tive group compared with 50% in the LOH-positive group (P =
0.06). Survival analysis was accordingly carried out in the group
of patients included in the recurrence analysis. In this group, the
result was very similar to that seen with the exclusion of Dukes’ D
and grade III patients. The 5-year cumulative survival rates of
LOH-positive patients (48%) and LOH-negative patients (79%)
differed significantly (P = 0.05).
In all these survival analyses, a marked difference in the
survival rates of LOH-positive and LOH-negative cases only
became apparent after a 3-year period. The effect of recurrence on
survival was studied by exclusion of all recurrent cases in the
survival analysis. The survival rates of LOH-positive and LOH-
negative patients were then similar to each other (Figure 3).
LOH positivity was related to poor survival in Dukes’ classes B
and C, as shown in Figure 4. In class B, the 5-year survival rate of
LOH-negative patients was 79%, compared with 57% in LOH-
positive patients. In Dukes’ class C, the corresponding percentages
were 44% and 21%. LOH positivity was not correlated to survival
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Table 3 Three-phase multivariate analysis for identification of prognostic
factors for colorectal cancer. Only those covariates that were statistically
significant in the analysis are presented. Phase I, all patients; phase II,
patients included in the recurrence analysis; phase III, Dukes’ class B
patients that were included in the recurrence analysis
Covariate Relative hazard 95% CI P-value Phase
Grade
I (ref) I
II 1.3 0.6–2.7 NS
III 3.2 1.2–8.2 0.01
Location (prox-dist) 1.9 0.9–3.9 0.05
Dukes’
A (ref)
B 2.1 0.7–5.8 NS
C 4.2 1.5–11.7 0.005
D 30 9.7–93 <0.001
Dukes’ II
A (ref)
B 2.0 0.67–6.0 NS
C 5.0 1.6–15.3 0.004
D 39 3.9–388 0.001
LOH 3.9 0.9–9.1 0.04 III
NS, not significant.
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Figure 3 Cumulative 5-year survival rates of LOH-positive (n = 63) and
LOH-negative (n = 73) patients with no tumour recurrence
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Figure 4 Cumulative 5-year survival rates of LOH-positive (n = 72) and
LOH-negative (n = 50) patients of Dukes’ classes B and C
Figure 5 Cumulative 5-year survival rates of LOH-positive (n = 80) and
LOH-negative (n = 66) patients with distally located tumoursin Dukes’ classes A and D.
The association between LOH and survival was further analysed
in relation to location of the primary tumour. As regards distal
tumours, the 5-year survival rate was 76% for LOH-negative
patients and 47% for LOH-positive patients (Figure 5). Patients
with proximal LOH-positive tumours had a survival rate only
slightly worse than that associated with LOH-negative ones.
DISCUSSION
Loss of heterozygosity at 18q21 in primary colorectal cancers was
studied in order to clarify its possible role as a marker of disease
outcome. Of the 195 informative cases, 52% were LOH positive, a
percentage somewhat lower than that reported in other studies.
Because of the very careful selection of sample tissues by two
experienced pathologists, it is unlikely that contamination by
normal tissue would have affected the result. Additionally, LOH
was most common in diseases of Dukes’ classes B and C, with
frequencies of LOH positivity of 56% and 64% respectively,
similar to those reported previously (60–67%) (O’Connell et al,
1992; Jen et al, 1994).
Our results show that LOH at 18q21 is correlated significantly
with the appearance of recurrent disease (P = 0.01). They also
show that LOH is associated with poor survival, and that this is
due to an increased rate of recurrence in LOH-positive tumours. Of
the primary tumours that recurred, 68% were LOH positive.
Additionally, LOH negativity indicated recurrence-free disease in
78% of the cases. LOH positivity and disease recurrence were
most commonly seen in patients belonging to Dukes’ classes B
and C. The higher rate of LOH positivity and recurrences seen in
distal compared with proximal cases may be related to the fact that
distal cancers were more often of Dukes’ classes B and C than the
proximal ones (data not shown). In survival analysis, those with
LOH-positive disease had a survival rate similar to that of LOH-
negative cases for the first 3 years. After that, the survival rate of
LOH-positive patients sharply decreased by 20%–27% compared
with that of LOH-negative patients (Figures 2, 4 and 5), resulting
in a marked difference in the survival rates of LOH-positive and
LOH-negative patients, which, however, as a result of limitations
in the survival analysis used, appeared statistically significant in
only one of the analyses. This decrease in the survival rate was
clearly associated with a higher rate of recurrence and subse-
quently an increased rate of cancer-related death in LOH-positive
cases compared with LOH-negative ones. The 3-year period of
similar survival rate of these two groups is the time during which
these recurrences develop (85% in 2 years) and patients with
recurrent disease begin to lose the fight against cancer and die (the
2-year survival rate after recurrence was 29%).
Additional analysis revealed that LOH positivity was signifi-
cantly correlated with poor survival in Dukes’ class B, and it also
indicated poor survival in class C, both being classes in which
most cases of recurrence developed (82%; Figure 4). The correla-
tion between LOH positivity and poor survival was markedly
clearer in distal than in proximal cancers, 87% of all recurrences
being in distal cancers (Figure 5). The difference seen in the
survival rates of LOH-positive and LOH-negative cases disap-
peared after exclusion of all the recurrent cases (Figure 3). Hence,
an increased rate of recurrence appears to be the reason for poor
survival among patients with LOH at 18q21 in primary tumours in
Dukes’ classes B and C.
The value of LOH at 18q as a prognostic indicator has been
assessed previously in a study by O’Connell et al (1992). They
suggested a possible correlation between LOH at 18q in Dukes’ B
and C tumours and poor survival. They also noticed an increased
rate of recurrence in LOH-positive cases, but the results were not
statistically significant because they had only 90 patients in the
study. Jen et al (1994) pointed out the importance of LOH in this
region in stage II tumours, with a survival rate of 54% in LOH-
positive patients compared with 93% in LOH-negative ones.
However, they found no such correlation as regards stage III
disease, and their study was not informative regarding the associa-
tion between LOH positivity and the rate of recurrent disease.
We detected LOH at 18q21 most commonly in Dukes’ B and C
tumours, a result similar to that of previous studies (Kikuchi-
Yanoshita et al, 1992; Iino et al, 1994). The rate of LOH in cases of
Dukes’ class D was somewhat lower than in cases of classes B and
C. This is contradictory, because genetic changes are known to
accumulate as cancer advances (Iino et al, 1994; Jen et al, 1994).
The LOH-positive tumours tended to be located more often in the
distal colon or rectum, as reported previously (Jen et al, 1994). The
correlation with mucinous tumour type was also similar to that
previously reported (Hedrick et al, 1994). The proportions of
LOH-positive and LOH-negative patients in the three histological
grades differed from those previously reported, apparently as a
consequence of different patient populations used in these studies.
Jen et al (1994) studied patients with disease stages II and III only,
whereas our patients were not selected according to the primary
stage of the disease. Variation in determination of histological
grade can also occur, depending on the person carrying out the
grading (Jen et al, 1994). We saw no correlation between the
appearance of LOH and the site of primary metastasis. Kato et al
(1996) found a correlation between LOH at 18q and liver metas-
tasis. However, they studied primarily metastatic and recurrent
tumours all as one group.
We conclude that LOH at 18q21 is a very important feature of
colorectal cancer progression, as our results suggest a central role
for it in recurrence development and thus in poor prognosis.
Examination of LOH at 18q21 in primary colorectal cancers of
Dukes’ classes B and C can help to find patients that are prone to
recurrence and consequently need intensified adjuvant therapy and
more careful follow-up.
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